Psoriasis pill could enter market early next year, people familiar say

FDA regulators aim to approve a new arthritis pill early in 2019 to treat the symptoms of psoriasis.

The food and drug administration (FDA) is aiming to approve a new arthritis pill early in 2019 to treat the symptoms of psoriasis.

Pfizer Inc plans to file for an early approval of an experimental drug called tanezumab (XL518) in the first three months of 2019, according to four people familiar with the matter. The company hopes to submit its drug to the FDA early next year in hopes of an early approval, meaning that it would be allowed to go on sale by the summer, said the people, who asked not to be identified discussing private matters.

Tanezumab was the last drug in a crowded field of new treatments for psoriasis. The FDA last month asked for additional clinical trials before it could approve the pill, which would limit its launch to adults with moderate to severe psoriasis. The proposed decision allows for a late 2018 or early 2019 start date, the people said.

Leave a Comment